Senior insider sale
Chief Commercial Officer at SYROS PHARMACEUTICALS, INC. — senior position signals high conviction
$24.4K
39.50K shares
What this filing means
CHEE CONLEY plans to sell 39.50K shares of SYROS PHARMACEUTICALS, INC. valued at approximately $24.4K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 11/18/2024ACC: 0001972362-24-001665
Officer· Chief Commercial Officer
Since Sep 2021
39.50K
Shares to sell
$24.4K
Approx. market value
30.80K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months4
RESTRICTED STOCK
COMPENSATION
10/31/2024
8.29KRESTRICTED STOCK
COMPENSATION
3/31/2024
10.17KRESTRICTED STOCK
COMPENSATION
10/31/2023
11KRESTRICTED STOCK
COMPENSATION
3/31/2023
1.34KTotal acquired30.80K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
10/31/2024 | RESTRICTED STOCK COMPENSATION | 8.29K | — |
3/31/2024 | RESTRICTED STOCK COMPENSATION | 10.17K | — |
10/31/2023 | RESTRICTED STOCK COMPENSATION | 11K | — |
3/31/2023 | RESTRICTED STOCK COMPENSATION | 1.34K | — |
| Total | 30.80K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
8.71K
Market value
$18.2K
11/1/2024
Planned — Approximate Date
NASDAQPlanned
Units to sell
30.80K
Market value
$6.1K
11/18/2024
Total
Units
39.50K
Value
$24.4K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
11/1/2024 | 8.71K | $18.2K | — | Completed |
| Planned — Approximate Date | ||||
11/18/2024 | 30.80K | $6.1K | NASDAQ | Planned |
| Total | 39.50K | $24.4K | ||